Eupraxia Pharmaceuticals Inc
TSX:EPRX
Income Statement
Earnings Waterfall
Eupraxia Pharmaceuticals Inc
Revenue
|
0
CAD
|
Operating Expenses
|
-27.4m
CAD
|
Operating Income
|
-27.4m
CAD
|
Other Expenses
|
-777.6k
CAD
|
Net Income
|
-28.2m
CAD
|
Income Statement
Eupraxia Pharmaceuticals Inc
Jun-2020 | Sep-2020 | Dec-2020 | Mar-2021 | Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | ||||||||||||||||
Revenue |
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
|
Operating Income | ||||||||||||||||
Operating Expenses |
(4)
|
(3)
|
(2)
|
(6)
|
(11)
|
(15)
|
(18)
|
(17)
|
(18)
|
(17)
|
(23)
|
(24)
|
(26)
|
(30)
|
(27)
|
|
Selling, General & Administrative |
(2)
|
(1)
|
(1)
|
(5)
|
(6)
|
(7)
|
(8)
|
(6)
|
(5)
|
(5)
|
(6)
|
(6)
|
(8)
|
(9)
|
(7)
|
|
Research & Development |
(2)
|
(1)
|
(1)
|
(1)
|
(5)
|
(8)
|
(10)
|
(11)
|
(12)
|
(13)
|
(17)
|
(18)
|
(18)
|
(20)
|
(21)
|
|
Depreciation & Amortization |
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
|
Other Operating Expenses |
(0)
|
(0)
|
(0)
|
0
|
0
|
0
|
(0)
|
0
|
0
|
0
|
(0)
|
(0)
|
(0)
|
(0)
|
0
|
|
Operating Income |
(4)
N/A
|
(3)
+27%
|
(2)
+7%
|
(6)
-167%
|
(11)
-67%
|
(15)
-41%
|
(18)
-21%
|
(17)
+9%
|
(18)
-7%
|
(17)
+1%
|
(23)
-31%
|
(24)
-6%
|
(26)
-6%
|
(30)
-15%
|
(27)
+8%
|
|
Pre-Tax Income | ||||||||||||||||
Interest Income Expense |
(2)
|
(2)
|
(1)
|
(2)
|
(2)
|
(2)
|
(2)
|
(1)
|
0
|
(0)
|
(1)
|
(0)
|
(6)
|
(4)
|
(1)
|
|
Non-Reccuring Items |
0
|
0
|
0
|
(2)
|
(3)
|
(3)
|
(3)
|
(1)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
|
Gain/Loss on Disposition of Assets |
(0)
|
(0)
|
(0)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(0)
|
0
|
(0)
|
(0)
|
(0)
|
|
Total Other Income |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(0)
|
|
Pre-Tax Income |
(5)
N/A
|
(5)
+13%
|
(4)
+12%
|
(11)
-167%
|
(16)
-46%
|
(20)
-26%
|
(23)
-18%
|
(18)
+22%
|
(18)
+2%
|
(18)
-1%
|
(24)
-31%
|
(25)
-4%
|
(33)
-31%
|
(34)
-4%
|
(29)
+14%
|
|
Net Income | ||||||||||||||||
Tax Provision |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(0)
|
|
Income from Continuing Operations |
(5)
|
(5)
|
(4)
|
(11)
|
(16)
|
(20)
|
(23)
|
(18)
|
(18)
|
(18)
|
(24)
|
(25)
|
(33)
|
(34)
|
(29)
|
|
Income to Minority Interest |
0
|
(0)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
1
|
1
|
1
|
|
Net Income (Common) |
(5)
N/A
|
(5)
+13%
|
(4)
+13%
|
(11)
-168%
|
(16)
-45%
|
(19)
-25%
|
(23)
-18%
|
(18)
+22%
|
(17)
+2%
|
(18)
-2%
|
(23)
-31%
|
(24)
-4%
|
(32)
-32%
|
(33)
-3%
|
(28)
+14%
|
|
EPS (Diluted) |
-0.42
N/A
|
-0.36
+14%
|
-0.31
+14%
|
-0.83
-168%
|
-1.19
-43%
|
-1.36
-14%
|
-1.85
-36%
|
-1.25
+32%
|
-0.67
+46%
|
-0.82
-22%
|
-1.21
-48%
|
-1.11
+8%
|
-1.17
-5%
|
-1.29
-10%
|
-1.17
+9%
|